Patients and families are filing (and investigating) lawsuits alleging the eczema/asthma drug Dupixent® (dupilumab) caused serious injuries—most notably cutaneous T-cell lymphoma (CTCL) and severe ocular complications (conjunctivitis/keratitis)—and that manufacturers failed to adequately warn about these risks. If you or a loved one used Dupixent and later developed lymphoma, persistent eye inflammation, vision problems, or other complications, you may be eligible for compensation.
Quick Facts
| Category | Detail |
| Program Name | Defective Drugs & Medical Devices |
| Administered By | Active investigations; individual lawsuits are being filed. As of December 2025, there is no MDL or class action specifically for Dupixent. |
| Drug / Manufacturer | |
| Eligibility Criteria | Used Dupixent for eczema |
| Key Allegations/Challenges | Failure to warn of potential CTCL/lymphoma risk; inadequate warnings and safeguards around serious ocular side effects (conjunctivitis, keratitis, corneal injury). |
| Compensation Types | Varies by severity and proof. Some plaintiff firms speculate ranges such as $100,000–$500,000 in severe CTCL cases—early, case-specific estimates only. |
| Appeal Options | Depends on your state’s statute of limitations and the discovery rule (when the injury was or should have been discovered). Act promptly to preserve your rights. |
What Is the Dupixent Lawsuit About?
Plaintiffs allege that Dupixent can mask or be associated with CTCL, a rare blood cancer that can resemble eczema—potentially leading to delayed diagnosis—and that the manufacturers failed to adequately warn about this risk. Separate claims focus on serious eye injuries (e.g., conjunctivitis, keratitis) documented in trials and post-marketing reports. Defendants deny wrongdoing.
Who Qualifies for This Lawsuit?
You may qualify if you (or your loved one):
- Used Dupixent for eczema (atopic dermatitis), asthma, COPD/CSU, or other approved indications; and later
- Were diagnosed with CTCL or another T-cell lymphoma, or suffered serious, persistent ocular injuries (conjunctivitis/keratitis with vision changes) documented by a clinician; and
- Have medical records (diagnoses, biopsy/pathology for lymphoma; ophthalmology notes for eye injuries), Dupixent treatment records, and evidence connecting use to harm; and
Injuries or Damages Reported
- Cutaneous T-cell lymphoma (CTCL) or related T-cell lymphomas following Dupixent use.
- Ocular complications: conjunctivitis, blepharitis, keratitis, dry eye; in rare cases, cicatricial disease/corneal ulcer and vision changes.
Medical expenses, lost income, pain & suffering; in fatal cases, wrongful-death damages.
FDA approvals for multiple conditions; label notes ocular adverse reactions (conjunctivitis/keratitis).
FDA approves Dupixent for certain COPD patients (add-on), expanding use.
First lawsuits filed alleging CTCL after Dupixent; reports of a Tennessee wrongful-death case (Nov 2025).
No MDL; firms continue investigations and filings nationwide.
How to File a Claim
- Fill out the short form below with your basic information.
- A participating attorney experienced in pharmaceutical injury will review your situation.
- If you qualify, your attorney will help collect medical/treatment records, pathology/ophthalmology reports, and proof of Dupixent use, then file your claim and pursue settlement or trial.
- No upfront cost — cases are typically on contingency (you pay only if compensation is recovered).
-
Does Dupixent “cause” cancer?
Causation is the central dispute. Lawsuits allege a link to CTCL and inadequate warnings; the FDA label does not list CTCL as a confirmed risk but law firms cite cases/studies raising concern. Courts will weigh expert evidence.
-
What eye problems are reported with Dupixent?
Clinical trials/post-marketing describe conjunctivitis and keratitis (sometimes with blurred vision); most cases are manageable, though severe/persistent disease has been reported.
-
Is there a Dupixent class action or MDL?
Not currently. As of December 2025, cases are early and individualized; no MDL has been formed.
-
What compensation could be available?
Highly variable and case-specific. Some firms suggest speculative ranges (e.g., $100k–$500k for severe CTCL), but outcomes depend on diagnosis severity, proof of causation, medical costs, and jurisdiction.
-
I used Dupixent years ago—can I still file?
Possibly. Many states apply a discovery rule (clock may start when you learned the injury could be linked). Act quickly to avoid missing deadlines.
-
Who are the defendants?
Sanofi and Regeneron, the developers/manufacturers of Dupixent.
-
How long will a case take?
Timelines vary. Some cases may resolve in early negotiations; others require full litigation. Your attorney can estimate based on your facts and jurisdiction.
